Oral anticoagulation during atrial fibrillation ablation: Facts and controversies

Cor et Vasa

Volumn 55, Issue 2, 2013, Pages

  Dorobantu, Maria ^a   Vatasescu, Radu ^b  

^a Emergency Hospital   (Romania)

^b Clinical Emergency Hospital   (Romania)

Author keywords

Atrial fibrillation; Catheter ablation; Heparin; Oral anticoagulants; Vitamin K antagonist

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIVITAMIN K; DABIGATRAN; FRESH FROZEN PLASMA; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; BRAIN ISCHEMIA; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; DRUG SAFETY; EMBOLISM; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART TAMPONADE; HEMATOTHORAX; HEMOPERICARDIUM; HIGH RISK PATIENT; HUMAN; PERCUTANEOUS DRAINAGE; PERICARDIAL EFFUSION; RETROPERITONEAL HEMORRHAGE; REVIEW; RISK FACTOR; SINUS RHYTHM; THROMBOEMBOLISM; THROMBUS;

EID: 84880042171     PISSN: 00108650     EISSN: 18037712     Source Type: Journal    
DOI: 10.1016/j.crvasa.2012.12.002     Document Type: Review

References (56)

1. A. S. Go, et al., Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study, Journal of the American Medical Association 285 (18) (2001) 2370-2375.
2. J. Heeringa, et al., Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study, European Heart Journal 27 (8) (2006) 949-953.
3. Y. Miyasaka, et al., Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence, Circulation 114 (2) (2006) 119-125.
4. V. L. Roger, et al., Heart disease and stroke statistics-2012 update: a report from the American Heart Association, Circulation 125 (1) (2012) e2-e220.
5. A. J. Camm, G. Y. H. Lipp, R. De Caterina, et al., 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation: Developed with the special contribution of the European Heart Rhythm Association, European Heart Journal 33 (2012) 2719-2747.
6. H. Calkins, et al., 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design, Journal of Interventional Cardiac Electrophysiology 33 (2) (2012) 171-257.
7. A. Raviele, et al., Venice Chart international consensus document on atrial fibrillation ablation: 2011 update, Journal of Cardiovascular Electrophysiology 23 (8) (2012) 890-923.
8. O. M. Wazni, et al., Cardiovascular imaging in the management of atrial fibrillation, Journal of the American College of Cardiology 48 (10) (2006) 2077-2084.
9. D. Scherr, et al., Incidence and predictors of left atrial thrombus prior to catheter ablation of atrial fibrillation, Journal of Cardiovascular Electrophysiology 20 (4) (2009) 379-384.
10. S. Puwanant, et al., Role of the CHADS2 score in the evaluation of thromboembolic risk in patients with atrial fibrillation undergoing transesophageal echocardiography before pulmonary vein isolation, Journal of the American College of Cardiology 54 (22) (2009) 2032-2039.
11. O. M. Wazni, et al., Embolic events and char formation during pulmonary vein isolation in patients with atrial fibrillation: impact of different anticoagulation regimens and importance of intracardiac echo imaging, Journal of Cardiovascular Electrophysiology 16 (6) (2005) 576-581.
12. D. Scherr, et al., Incidence and predictors of periprocedural cerebrovascular accident in patients undergoing catheter ablation of atrial fibrillation, Journal of Cardiovascular Electrophysiology 20 (12) (2009) 1357-1363.
13. R. Cappato, et al., Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation, Circulation: Arrhythmia and Electrophysiology 3 (1) (2010) 32-38.
14. F Gaita, et al., Radiofrequency catheter ablation of atrial fibrillation: a cause of silent thromboembolism? Magnetic resonance imaging assessment of cerebral thromboembolism in patients undergoing ablation of atrial fibrillation, Circulation 122 (17) (2010) 1667-1673.
15. C. Herrera Siklody, T. Deneke, M. Hocini, et al., Incidence of asymptomatic intracranial embolic events after pulmonary vein isolation: comparison of different atrial fibrillation ablation technologies in a multicenter study, Journal of the American College of Cardiology 58 (7) (2011) 681-688.
16. T. Neumann, et al., MEDAFI-Trial (Micro-embolization during ablation of atrial fibrillation): comparison of pulmonary vein isolation using cryoballoon technique vs. radiofrequency energy, Europace 13 (1) (2011) 37-44.
17. B. Cauchemez, et al., High-flow perfusion of sheaths for prevention of thromboembolic complications during complex catheter ablation in the left atrium, Journal of Cardiovascular Electrophysiology 15 (3) (2004) 276-283.
18. N. Dagres, et al., Complications of atrial fibrillation ablation in a high-volume center in 1, 000 procedures: still cause for concern?, Journal of Cardiovascular Electrophysiology 20 (9) (2009) 1014-1019.
19. A. Verma, B. Tsang, The use of anticoagulation during the periprocedure period of atrial fibrillation ablation, Current opinion in cardiology 27 (1) (2012) 55-61.
20. R. Cappato, et al., Prevalence and causes of fatal outcome in catheter ablation of atrial fibrillation, Journal of the American College of Cardiology 53 (19) (2009) 1798-1803.
21. R. U. Shah, et al., Procedural complications, rehospitalizations, and repeat procedures after catheter ablation for atrial fibrillation, Journal of the American College of Cardiology 59 (2) (2012) 143-149.
22. N. Lellouche, et al., Acute pericardial effusion following atrial fibrillation ablation: characteristics and relationship with arrhythmia recurrences, Archives of Cardiovascular Diseases 104 (8-9) (2011) 450-457.
23. F Abhishek, et al., Effectiveness of a strategy to reduce major vascular complications from catheter ablation of atrial fibrillation, Journal of Interventional Cardiac Electrophysiology 30 (3) (2011) 211-215.
24. H. Hoyt, et al., Complications arising from catheter ablation of atrial fibrillation: temporal trends and predictors, Heart Rhythm 8 (12) (2011) 1869-1874.
25. D. Gopinath, et al., Pulmonary vein antrum isolation for atrial fibrillation on therapeutic coumadin: special considerations, Journal of Cardiovascular Electrophysiology 22 (2) (2011) 236-239.
26. O. M. Wazni, et al., Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period, Circulation 116 (22) (2007) 2531-2534.
27. A. Tischenko, et al., Implantation of cardiac rhythm devices without interruption of oral anticoagulation compared with perioperative bridging with low-molecular weight heparin, American Heart Journal 158 (2) (2009) 252-256.
28. J. M. Tolosana, et al., Preparation for pacemaker or implantable cardiac defibrillator implants in patients with high risk of thrombo-embolic events: oral anticoagulation or bridging with intravenous heparin? A prospective randomized trial, European Heart Journal 30 (15) (2009) 1880-1884.
29. P. P. Karjalainen, et al., Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment, European Heart Journal 29 (8) (2008) 1001-1010.
30. K. E. Airaksinen, et al., Safety of coronary artery bypass surgery during therapeutic oral anticoagulation, Thrombosis Research 128 (5) (2011) 435-439.
31. A. A. Hussein, et al., Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: a safe and efficacious periprocedural anticoagulation strategy, Heart Rhythm 6 (10) (2009) 1425-1429.
32. R. Cappato, et al., Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation, Circulation 111 (9) (2005) 1100-1105.
33. M. Martinek, et al., Asymptomatic cerebral lesions during pulmonary vein isolation under uninterrupted oral anticoagulation, Europace 15 (3) (2013) 325-331.
34. H. Ichiki, et al., Incidence of asymptomatic cerebral microthromboembolism after atrial fibrillation ablation guided by complex fractionated atrial electrogram, Journal of Cardiovascular Electrophysiology 23 (6) (2012) 567-573.
35. L. Di Biase, et al., Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio, Circulation 121 (23) (2010) 2550-2556.
36. R. Latchamsetty, et al., Management and outcomes of cardiac tamponade during atrial fibrillation ablation in the presence of therapeutic anticoagulation with warfarin, Heart Rhythm 8 (6) (2011) 805-808.
37. A. Majeed, et al., Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy, Thrombosis Research 129 (2) (2012) 146-151.
38. S. Gautam, et al., Effect of therapeutic INR on activated clotting times, heparin dosage, and bleeding risk during ablation of atrial fibrillation, Journal of Cardiovascular Electrophysiology 22 (3) (2011) 248-254.
39. J. J. Kwak, et al., Safety and convenience of continuous warfarin strategy during the periprocedural period in patients who underwent catheter ablation of atrial fibrillation, Journal of Cardiovascular Electrophysiology 21 (6) (2010) 620-625.
40. S. P. Page, et al., Catheter ablation for atrial fibrillation on uninterrupted warfarin: can it be done without echo guidance?, Journal of Cardiovascular Electrophysiology 22 (3) (2011) 265-270.
41. A. Hakalahti, et al., Catheter ablation of atrial fibrillation in patients with therapeutic oral anticoagulation treatment, Europace 13 (5) (2011) 640-645.
42. P. Santangeli, et al., Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications: evidence from a meta-analysis, Circulation. Arrhythmia and Electrophysiology 5 (2) (2012) 302-311.
43. E. Arbelo, et al., ESC-EURObservational research programme: the Atrial Fibrillation Ablation Pilot Study, conducted by the European Heart Rhythm Association, Europace 14 (8) (2012) 1094-1103.
44. G. Y. Lip, et al., Periprocedural anticoagulation therapy for devices and atrial fibrillation ablation, Europace 14 (5) (2012) 741-744.
45. S. J. Connolly, et al., Dabigatran versus warfarin in patients with atrial fibrillation, The New England Journal of Medicine 361 (12) (2009) 1139-1151.
46. M. R. Patel, et al., Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, The New England Journal of Medicine 365 (10) (2011) 883-891.
47. J. S. Healey, et al., Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial, Circulation 126 (3) (2012) 343-348.
48. D. Lakkireddy, et al., Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry, Journal of the American College of Cardiology 59 (13) (2012) 1168-1174.
49. J. Douxfils, et al., Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate, Thrombosis and Haemostasis 107 (5) (2012) 985-997.
50. J. van Ryn, et al., Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity, Thrombosis and Haemostasis 103 (6) (2010) 1116-1127.
51. D. Snipelisky, et al., A comparison of bleeding complications post-ablation between warfarin and dabigatran, Journal of Interventional Cardiac Electrophysiology 35 (1) (2012) 29-33.
52. K. Kaseno, et al., Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation, Circulation Journal 76 (10) (2012) 2337-2342.
53. R. A. Winkle, et al., The use of dabigatran immediately after atrial fibrillation ablation, Journal of Cardiovascular Electrophysiology 23 (3) (2012) 264-268.
54. E. S. Eerenberg, et al., Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects, Circulation 124 (14) (2011) 1573-1579.
55. M. E. Mortada, et al., Periprocedural anticoagulation for atrial fibrillation ablation, Journal of Cardiovascular Electrophysiology 19 (4) (2008) 362-366.
56. TJ. Bunch, et al., Warfarin is not needed in low-risk patients following atrial fibrillation ablation procedures, Journal of Cardiovascular Electrophysiology 20 (9) (2009) 988-993.